BioNews Texas |
A simpler way to predict heart failure
Longview News-Journal HOUSTON — (Sept. 16, 2013) – Predicting the future just got a little clearer – when it comes to the likelihood of heart failure, that is. The levels of two biomarkers in the bloodstream were found to significantly improve our ability to identify who … BCM Researchers Discover Simpler, Improved Biomarkers to Predict Heart …BioNews Texas |
DGU organises blood donation drive in Dmu – Nagaland Post
|
DGU organises blood donation drive in Dmu
Nagaland Post Dimapur Gorkha Union successfully organized a blood donation drive at Dimapur on September 14 in memory of the 1st Gorkha Martyr Maj Durga Malla and Kargil Martyr from Nagaland Capt. N. Kenguruse under the theme “Don’t shed blood donate blood”. |
New Treanda Formulation Approved – Monthly Prescribing Reference
Monthly Prescribing Reference |
New Treanda Formulation Approved
Monthly Prescribing Reference Treanda is an alkylating agent currently approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab or rituximab-containing regimen. |
Minahans to receive honor from organ donation group – Tbo.com
|
Minahans to receive honor from organ donation group
Tbo.com PALMA CEIA — Two longtime supporters of organ donation and transplant will be honored with an award to be named for them. Bill and Martha Minahan, who reside in Hunter’s Green in New Tampa, will be the first recipients of the Bill & Martha Minahan … |
FDA Approves Teva's TREANDA® (bendamustine HCI) Injection, a New Liquid … – DailyFinance
|
FDA Approves Teva’s TREANDA® (bendamustine HCI) Injection, a New Liquid …
DailyFinance TREANDA is indicated for use in patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen, and in patients with chronic lymphocytic leukemia … |
Bullish On Halozyme With Short Term Catalysts And Large Buy By A Jazz … – Trefis
|
Bullish On Halozyme With Short Term Catalysts And Large Buy By A Jazz …
Trefis The second therapy is MabThera SC, or Rituximab, with trade name Rituxan. Rituxan was approved in the US in 1997 for the treatment of non-Hodgkin’s lymphoma. With validation of the approval of the monoclonal antibody Herceptin SC, it’s looking like … |
BIOLINERX LTD. : BioLineRx Announces Receipt of a Notice of Allowance from … – 4-traders (press release)
BIOLINERX LTD. : BioLineRx Announces Receipt of a Notice of Allowance from …4-traders (press release)According to a 2011 report from Decision Resources, about 180 million people worldwide are chronically infected with HCV. In addition, HCV infection …
TEVA PHARMACEUTICAL INDUSTRIES LIMITED : FDA Approves Teva's … – 4-traders (press release)
Monthly Prescribing Reference |
TEVA PHARMACEUTICAL INDUSTRIES LIMITED : FDA Approves Teva’s …
4-traders (press release) TREANDA is indicated for use in patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen, and in patients with chronic lymphocytic leukemia … New Treanda Formulation ApprovedMonthly Prescribing Reference FDA approves Teva’s injectable TreandaGlobes |
FDA approves Teva's injectable Treanda – Globes
|
FDA approves Teva’s injectable Treanda
Globes … (FDA) has approved a new injectable version Treanda for treatment of indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen, and chronic lymphocytic leukemia. |
Why Belgian and Dutch organ donation data are so different – Livemint
LivemintWhy Belgian and Dutch organ donation data are so differentLivemintThe Netherlands got this number of 28% after a very heavy advertising campaign, with millions spent on publicity, public outreach and a soap opera to make people sensitive to don…